69038-81-9

Basic information

• Product Name: 2-ETHOXYCINNAMIC ACID
• Synonyms: (E)-3-(2-ETHOXY-PHENYL)-ACRYLIC ACID;(2E)-3-(2-Ethoxyphenyl)-2-propenoic acid;Propenoic acid, 3-(2-ethoxyphenyl)-;2-Ethoxycinnanic acid;2-Ethoxycinnamic acid, 98+%;2-Ethoxyciamic acid;RARECHEM BK HW 0104;O-ETHOXYCINNAMIC ACID
• CAS NO: 69038-81-9
• Molecular Formula: C₁₁H₁₂O₃
• Molecular Weight: 192.21
• Product Categories: Aromatic Cinnamic Acids, Esters and Derivatives;C11 to C12;Carbonyl Compounds;Carboxylic Acids;Building Blocks;C11 to C12;Carbonyl Compounds;Carboxylic Acids;Chemical Synthesis;Organic Building Blocks
• Mol File: 69038-81-9.mol
• Article Data: 2

Chemical Properties

• Melting Point: 134-138 °C(lit.)
• Boiling Point: 337.161 °C at 760 mmHg
• Flash Point: 131.71 °C
• Appearance: /
• Density: 1.161 g/cm³
• Vapor Pressure: 4.18E-05mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• BRN: 2693328
• CAS DataBase Reference: 2-ETHOXYCINNAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ETHOXYCINNAMIC ACID(69038-81-9)
• EPA Substance Registry System: 2-ETHOXYCINNAMIC ACID(69038-81-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 69038-81-9(Hazardous Substances Data)

Usage

General Description

2-Ethoxycinnamic acid, also known as 3-(2-ethoxyphenyl)acrylic acid, is a chemical compound with the molecular formula C11H12O3. It is a derivative of cinnamic acid, with an additional ethoxy group attached to the benzene ring. 2-Ethoxycinnamic acid is commonly used in organic synthesis and pharmaceutical research due to its potential therapeutic properties. It has been studied for its anti-inflammatory, anti-tumor, and antioxidant properties, as well as its potential as a UV-absorbing agent. 2-Ethoxycinnamic acid is also utilized in the production of fragrances and flavorings as well as in the manufacturing of polymer materials. Its unique chemical structure and diverse range of applications make it a valuable compound in various industries.

InChI:InChI=1/C11H12O3/c1-2-14-10-6-4-3-5-9(10)7-8-11(12)13/h3-8H,2H2,1H3,(H,12,13)/b8-7+

Upstream product

• 110-86-1 pyridine 
• 141-82-2 malonic acid 
• 613-69-4 2-ethoxylbenzaldehyde 
• 64-19-7 acetic acid 

Downstream Products

• 1429518-81-9 5-(2-ethoxyphenyl)-4,5-dihydro-[1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline 
• 1373209-39-2 (-)-(S)-8-(2-ethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one 
• 1373209-40-5 (+)-(R)-8-(2-ethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one 
• 599151-35-6 8-(2-ethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6-(5H)-one 
• 1429518-86-4 8-(2-ethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-6(5H)-thione 
• 70842-56-7 1-[3-(2-ethoxy-phenyl)-acryloyl]-piperazine 
• 84050-32-8 (E)-1-[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperazin-1-yl]-3-(2-ethoxy-phenyl)-propenone; hydrochloride 

Relevant articles and documents

Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP

CGRP, known as the most potent vasodilator substance, plays an important role in hypertension initiation and development. TRPV1 and TRPA1 are critical in promoting the synthesis and release of CGRP, thereby regulating the cardiovascular tone. Rutaecarpine exhibits potent vasodilator and hypertensive effects by stimulating CGRP synthesis and release via activation of TRPV1. And NO has been shown to react with H2S in vivo to form HNO, thereby activating HNO-TRPA1-CGRP pathway. Inspired by combination therapy, 11 rutaecarpine-furoxan hybrids were designed, synthesized and evaluated. The results demonstrated that most hybrids exerted comparable or improved vasodilator activities. Among which, 13a is the most potent both ex vivo (EC50 = 13.1 nM) and in vivo. Mechanistic studies revealed that the vasodilator and anti-hypertensive effects of the hybrids might involve the promotion of CGRP release via dual activation of TRPV1 and TRPA1. This work suggests that dual-targeted hybrids might be an effective and promising approach to discover and develop novel anti-hypertensive drugs.